Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. (Q54391141)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

author name string

Richard Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

Ann Tan

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

Kevin K Lai

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

John Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

Yixen Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

Lisa A Rybicki

6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

Xiulu Liu

7

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

language of work or name

0 references

publication date

24 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

117

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

14

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

3126-3134

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Ribonucleotide reductase: regulation, regulation, regulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

From RNA to DNA, why so many ribonucleotide reductases?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Discovery of novel tumor markers of pancreatic cancer using global gene expression technology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25883

21 January 2018

Identifiers

10.1002/CNCR.25883

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/21264835

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54391141&oldid=1047892348"